Surrozen (SRZN) Non Operating Investment Income (2020 - 2023)
Surrozen (SRZN) posted quarterly Non Operating Investment Income of -$1000.0 for Q4 2023, down 100.55% year-over-year from $183000.0 in Q4 2022, and up 75.0% quarter-over-quarter from -$4000.0 in Q3 2023.
Powered by 
Analysis
Surrozen (SRZN) Non Operating Investment Income (2020 - 2023) Analysis & Trends
Surrozen's Non Operating Investment Income history runs 4 years deep, the most recent figure standing at -$1000.0 for Q4 2023.
- In Q4 2023, Non Operating Investment Income fell 100.55% year-over-year to -$1000.0; the TTM figure through Sep 2024 stood at -$1000.0 (down 100.24% YoY), while the FY2023 annual figure was $241000.0, up 297.54% from the prior year.
- Non Operating Investment Income for Q4 2023 stood at -$1000.0, up from -$4000.0 in the prior quarter.
- The five-year high for Non Operating Investment Income was $191000.0 in Q1 2023, with the low at -$310000.0 in Q1 2022.
- The 4-year median for Non Operating Investment Income is -$4000.0 (2023), against an average of -$762.82.
- The sharpest annual moves came in 2021 and 2022: Non Operating Investment Income sank 1127.51% in 2021, then jumped 425.0% in 2022.
- Surrozen's Non Operating Investment Income stood at -$8391.0 in 2020, then tumbled by 1127.51% to -$103000.0 in 2021, then surged by 277.67% to $183000.0 in 2022, then sank by 100.55% to -$1000.0 in 2023.
- Business Quant data shows SRZN's Non Operating Investment Income at -$1000.0 in Q4 2023, -$4000.0 in Q3 2023, and $55000.0 in Q2 2023.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | - |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | - |
| 10 | Surrozen | 259.50 Mn | 259.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2023 | -1,000.00 |
| Sep 30, 2023 | -4,000.00 |
| Jun 30, 2023 | 55,000.00 |
| Mar 31, 2023 | 191,000.00 |
| Dec 31, 2022 | 183,000.00 |
| Sep 30, 2022 | 52,000.00 |
| Jun 30, 2022 | -47,000.00 |
| Mar 31, 2022 | -310,000.00 |
| Dec 31, 2021 | -103,000.00 |
| Sep 30, 2021 | -16,000.00 |
| Dec 31, 2020 | -8,391.00 |